Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms START-CKD
- Sponsors Amgen
- 24 Oct 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017, reported by ClinicalTrials.gov record.
- 15 Feb 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2017 as reported by ClinicalTrials.gov record.